## Gian Pio Sorice

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2149919/publications.pdf

Version: 2024-02-01

430874 434195 1,502 32 18 31 citations h-index g-index papers 33 33 33 2873 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis. Frontiers in Endocrinology, 2022, 13, 846903.	3.5	8
2	Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. Metabolites, 2022, 12, 183.	2.9	31
3	Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity. International Journal of Molecular Sciences, 2022, 23, 7349.	4.1	26
4	Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. Diabetes Therapy, 2021, 12, 2101-2113.	2.5	6
5	Regarding "Fatal adrenal crisis due to Addison's disease arising in the context of autoimmune polyglandular syndrome type 1― Forensic Science, Medicine, and Pathology, 2021, , .	1.4	O
6	Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis. Scientific Reports, 2020, 10, 20070.	3.3	6
7	Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2685-2694.	3.6	6
8	Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovascular Diabetology, 2019, 18, 20.	6.8	101
9	Effect of Vitamin D Supplementation on Obesityâ€Induced Insulin Resistance: A Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Obesity, 2018, 26, 651-657.	3.0	33
10	Increased $\hat{l}^2$ -Cell Workload Modulates Proinsulin-to-Insulin Ratio in Humans. Diabetes, 2018, 67, 2389-2396.	0.6	37
11	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy, 2017, Volume 11, 2905-2919.	4.3	67
12	Metabolic consequences of the occlusion of the main pancreatic duct with acrylic glue after pancreaticoduodenectomy. American Journal of Surgery, 2015, 210, 783-789.	1.8	15
13	HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH. PLoS ONE, 2014, 9, e97136.	2.5	76
14	Insulin Resistance Alters Islet Morphology in Nondiabetic Humans. Diabetes, 2014, 63, 994-1007.	0.6	152
15	IL-21 Is a Major Negative Regulator of IRF4-Dependent Lipolysis Affecting Tregs in Adipose Tissue and Systemic Insulin Sensitivity. Diabetes, 2014, 63, 2086-2096.	0.6	49
16	Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney. American Journal of Physiology - Cell Physiology, 2014, 306, C202-C211.	4.6	15
17	Peroxiredoxin 6, a Novel Player in the Pathogenesis of Diabetes. Diabetes, 2014, 63, 3210-3220.	0.6	103
18	Blockade of receptor activator of nuclear factor-ÎB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nature Medicine, 2013, 19, 358-363.	30.7	211

#	Article	IF	Citations
19	Removal of Duodenum Elicits GLP-1 Secretion. Diabetes Care, 2013, 36, 1641-1646.	8.6	28
20	Vitamin D Deficiency: A New Risk Factor for Type 2 Diabetes. Annals of Nutrition and Metabolism, 2012, 61, 337-348.	1.9	97
21	Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 81-87.	2.6	108
22	Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach. Current Vascular Pharmacology, 2011, 9, 572-584.	1.7	4
23	The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship?. Clinical Endocrinology, 2011, 74, 300-305.	2.4	38
24	In anorexia nervosa, even a small increase in abdominal fat is responsible for the appearance of insulin resistance. Clinical Endocrinology, 2011, 75, 202-206.	2.4	27
25	Metabolic Syndrome in Transplant Patients: An Academic or a Health Burden?. Transplantation Proceedings, 2011, 43, 313-317.	0.6	10
26	Critical role of chemokine (C-C motif) receptor 2 (CCR2) in the KKAy + Apoe $\hat{a}^2/\hat{a}^2$ mouse model of the metabolic syndrome. Diabetologia, 2011, 54, 2660-2668.	6.3	14
27	Singleâ€fiber conduction velocity test allows earlier detection of abnormalities in diabetes. Muscle and Nerve, 2011, 43, 652-656.	2.2	7
28	Will vitamin D reduce insulin resistance? Still a long way to go. American Journal of Clinical Nutrition, 2011, 93, 672-673.	4.7	1
29	Association of Vitamin D With Insulin Resistance and $\hat{I}^2$ -Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. Diabetes Care, 2010, 33, e99-e99.	8.6	5
30	25â€Hydroxyvitamin D Concentration Correlates With Insulinâ€Sensitivity and BMI in Obesity. Obesity, 2010, 18, 1906-1910.	3.0	122
31	Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 365-377.	2.6	88
32	A combination of PPAR- $\hat{l}^3$ agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes). Medical Hypotheses, 2009, 73, 614-618.	1.5	11